Article Versions Notes

Hedemann N, Herz A, Schiepanski JH, Dittrich J, Sebens S, Dempfle A, Feuerborn J, Rogmans C, Tribian N, Flörkemeier I, et al. ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. Cancers. 2021; 13(9):2039. https://doi.org/10.3390/cancers13092039

Hedemann, Nina, Andreas Herz, Jan Hendrik Schiepanski, Jan Dittrich, Susanne Sebens, Astrid Dempfle, Julia Feuerborn, Christoph Rogmans, Nils Tribian, Inken Flörkemeier, and et al. 2021. "ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids" Cancers 13, no. 9: 2039. https://doi.org/10.3390/cancers13092039

Hedemann, N., Herz, A., Schiepanski, J. H., Dittrich, J., Sebens, S., Dempfle, A., Feuerborn, J., Rogmans, C., Tribian, N., Flörkemeier, I., Weimer, J., Krüger, S., Maass, N., & Bauerschlag, D. O. (2021). ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. Cancers, 13(9), 2039. https://doi.org/10.3390/cancers13092039